TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06798896: RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Sponsor: Supernus Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 216 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT06798896 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06798896 Rescue Dossier →